Sana Biotechnology to Present Preclinical Data on In Vivo CAR T Candidate SG293 at ASGCT 2026
Sana Biotechnology will present preclinical data for SG293, an in vivo CAR T candidate, at ASGCT 2026. The presentation covers a CD8-targeted fusosome that generates CD19-directed CAR T cells in NHPs.
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.
The presentation, titled "Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293," is part of the session "Advancing in vivo gene delivery with non-AAV viral vector systems" (MCEC Room 257AB, Level 2) on Tuesday, May 12, 2026, from 8:00–9:45 a.m. ET; the presentation is scheduled for 8:15–8:30 a.m. ET. The abstract number is 20 and is available to the public at the ASGCT annual meeting website.
SG293 represents a differentiated approach for enabling potent and precise in vivo CAR T therapy for both oncology and autoimmune indications, potentially avoiding key off-target concerns. SG293 uses Sana's proprietary fusogen-based delivery technology; it is a CD8-targeted fusosome that delivers to CD8+ T cells the genetic material to make CD19-directed CAR T cells while avoiding potentially troublesome delivery to tissues such as the liver. The fusogen technology is designed to enable cell-specific delivery of material that integrates into the DNA of the target cell. Sana intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases.
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. The company has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA.